Vortragsreihe SFB/TR209 / FOR2314 / CCC-TS
"Mechanisms of anti-PD1 induced skin toxicity"
Immunotherapy has ushered in a new era of cancer treatment, leading to significant and sustained improvement in patient survival. Although checkpoint inhibitors are now regarded pivotal in modern oncology, response rates among patients show inexplicable variation. The Flatz lab's IMIT-project (Immune-Monitoring of ImmunoTherapy) aims at identifying and functionally exploring changes in patients receiving checkpoint inhibitors. In the future, this will help to tailor individualized therapies for patients by predicting the best response to the growing arsenal of emerging checkpoint inhibitors.
